Paris-based MedTech startup SafeHeal secured a €10 million extension to its Series C funding round. Asabys Partners, via its Sabadell Asabys II fund, led this additional investment. This funding aims to transform colorectal surgery for cancer patients.
SafeHeal develops Colovac, a flexible endoluminal bypass sheath. This device offers an alternative to diverting ostomy for patients undergoing colorectal surgery. Colovac reduces fecal contact at the anastomotic site, promoting natural healing. It remains in place for approximately 10 days. An endoscopic procedure then removes the device, avoiding a second surgery. This approach allows patients to resume normal life without ostomy complications.
Advancing Colovac for Enhanced Patient Recovery
The €10 million extension builds on an oversubscribed €35 million Series C round. Asabys Partners joins a syndicate including Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis, and M&L Healthcare. Josep Ll. Sanfeliu, Managing Partner at Asabys, now joins SafeHeal’s Board of Directors.
This new capital will accelerate SafeHeal’s pivotal U.S. IDE study. Furthermore, it supports the planned commercial launch of Colovac in the EU. The company's focus on patient recovery aligns with broader trends in medical devices innovation, where firms like Intuitive Surgical and Medtronic also push surgical boundaries.
